Aberrant overexpression of the c-rel protooncogene is associated with lymphoid malignancy, while c-rel deletion produces severe lymphoproliferative defects and immunodeficiency. To investigate the mechanism of c-rel-induced proliferation and cell cycle progression in B lymphocytes, we have compared signaling events elicited through the BCR in c-rel À/À and wild-type B cells. BCR stimulation of c-rel À/À B cells fails to induce proper cyclin expression, resulting in G 1 phase arrest, but it is unclear whether these defects are in fact secondary events of decreased B-cell survival, since c-rel deletion also affects the expression of antiapoptotic genes such as bcl-x L . Here, we use the bclx L transgene to correct the viability of c-rel-deficient B cells, and show that the inhibition of apoptosis does not necessarily confer hyperproliferation of B cells activated through the BCR. c-rel À/À B cells still fail to enter the S phase despite improved survival by bcl-x L overexpression, suggesting that c-Rel-associated cell cycle progression is dependent on more than just enhanced cell viability. Overexpression of cyclin E protein, however, can cooperate with Bcl-x L to restore cell cycle progression to crel À/À B cells via induction of the cyclin-CDK/Rb-E2F pathway. Furthermore, we show that c-Rel can directly regulate transcription of the e2f3a promoter/enhancer, which is then likely to lead to transcriptional activation of the cyclin E promoter by E2F3a. Hence, these studies provide clear evidence that control of lymphocyte proliferation via c-Rel is linked to a cyclin-dependent process, and suggest that c-Rel not only activates antiapoptotic signaling but also the induction of cell cycle progression.
Introduction
Signals delivered through the B-cell antigen receptor (BCR) promote the proliferation and survival of antigen-specific B cells necessary for the defense against pathogenic infection. However, BCR signaling also triggers apoptosis in B cells that have been previously activated during an immune response or that possess self-reactivity. This feature of BCR signaling is an important function of lymphocyte homeostasis and immunological tolerance that protects against autoimmune disease and lymphoid outgrowth through the removal of activated or self-reactive B cells by cell cycle arrest and deletion (Carman et al., 1996; Healy and Goodnow, 1998; Monroe, 2000) . A shift in the balance of these events can therefore lead to the dysregulation of the immune system and potentiates the risk for development of B-cell malignancies or autoimmunity.
In B cells, NF-kB/Rel activation by BCR ligation is a primary event that promotes cell cycle progression and antiapoptotic signaling during an immune response. Five members of the NF-kB/Rel transcription factor family exist in mammals: p50 (nf-kb1), p52 (nf-kb2), p65 (rel A), rel B, and c-rel Ghosh and Karin, 2002; Liou, 2002) . The c-rel gene, in particular, is closely related to the avian v-rel oncogene, which was subsequently discovered to be responsible for numerous B-cell lymphomas in a number of avian species (Gilmore, 1999; Rayet and Gelinas, 1999) . Several mutations in the v-rel gene, particularly alterations and truncations of the C-terminal transactivation domain, confer its potent transforming potential and ability to induce tumors in various cells types of avian and mammalian origin, both in vitro and in vivo (Carrasco et al., 1996; Gilmore et al., 1996; Gilmore, 1999; Rayet and Gelinas, 1999; Gilmore et al., 2001 ). Likewise, mutation or overexpression of mammalian crel can transform primary chicken spleen cells, an effect that is accelerated by coexpression of bcl-2 or bcl-x L (Gilmore et al., 1996 (Gilmore et al., , 1999 Rayet and Gelinas, 1999; Gilmore et al., 2001; Rayet et al., 2003) . In humans, overexpression or amplification of the c-rel gene is also frequently associated with B-cell leukemias and lymphomas (Houldsworth et al., 1996; Joos et al., 1996; Rao et al., 1998; Rayet and Gelinas, 1999; Furman et Barth et al., 2003) . Thus, a feasible cure or treatment for many of these diseases may lie in the identification of the mechanism by which c-Rel controls cellular proliferation.
Mice carrying homozygous deletions of the c-rel gene show that BCR-induced B-cell expansion is prevented by cell cycle arrest and apoptosis. c-rel À/À B cells are blocked in G 1 phase and fail to progress through the cell cycle, and are also hypersensitive to irradiation, dexamethasone, and BCR-mediated cell death due to loss of c-Rel-dependent bfl-1 and bcl-x L transcription (Grumont et al., 1999; Lee et al., 1999; Zong et al., 1999; Chen et al., 2000; Owyang et al., 2001; Hsia et al., 2002; Edelstein et al., 2003) . Although it is speculated that crel-associated tumorigenesis is related to the overexpression of Bcl-x L , it is interesting to note that bcl-x L transgenic mice are not predisposed to tumors or lymphoproliferative diseases, indicating that additional events are necessary for tumor initiation. As c-Rel activates not only survival genes but also proliferation signaling, it is possible that c-Rel's activity is also linked to control of the cell cycle. The mechanism by which this occurs remains unclear, but is fundamental to understanding the underlying biology of lymphoproliferative diseases and autoimmune disorders associated with constitutive c-rel activity Hinz et al., 2001; Hilliard et al., 2002; Joos et al., 2002; Liu and Beller, 2002) .
The goal of these studies therefore, is to understand the molecular events responsible for these phenomena and determine if overexpression of survival genes, cell cycle genes, or both, are necessary elements in the establishment of B-cell proliferation by c-Rel. Using bclx L transgenic mice intercrossed with c-rel knockout mice, our data indicate that c-Rel-regulated lymphocyte proliferation is critically dependent upon cyclinmediated cyclin-dependent kinase (CDK) complexes in addition to the induction of bcl-x L -mediated survival, and suggests a model to describe the delicate balance of c-Rel activity in the prevention or promotion of lymphocyte expansion.
Results

BCR-activated c-rel
; bcl-x L Tg B cells fail to proliferate Previously, we and others have reported that the antiapoptotic gene, bcl-x L , is a direct target gene of cRel during BCR and CD40 stimulation of mouse B lymphocytes Owyang et al., 2001) . Hence, c-rel-deficient mice expressing the bcl-x L transgene are corrected for survival defects against a variety of cellular insults, including BCR-induced apoptosis. 
We have discovered that Bcl-x L expression is not sufficient, however, to restore proliferation responses to BCR-activated c-rel À/À B cells. Thymidine incorporation data show that c-rel
; bcl-x L Tg B cells fail to proliferate when stimulated through the BCR with antiIgM ( Figure 1a ). Cell cycle analysis using propidium iodide (PI) to measure DNA content also indicates that fewer cells enter the cell cycle, despite an overall reduction in apoptosis. Only 5% of c-rel
; bcl-x L Tg B cells contain 42N DNA (representing S, G 2 , and M phases) compared with 22% of c-rel (Figure 1b) . Exclusion of apoptotic cells (o2N DNA) reveals that more than 90% of the viable c-rel
bcl-x L Tg population are in fact arrested in G 1 compared with only 68% of viable c-rel þ / þ ; bcl-x L Tg B cells. To further examine the effects of the bcl-x L transgene on c-rel À/À B-cell cycle progression, we analysed antiIgM-stimulated c-rel
; bcl-x L Tg B cells compared with wild-type cells by 5-(and-6)-carboxyfluoresceindiacetate succinimidyl ester (CFSE) labeling. CFSE is a stable fluorescent intracellular marker that allows monitoring of individual cells for proliferation based on the decrease in fluorescence intensity upon cell division. Figure 1c shows that c-rel
; bcl-x L Tg B cells treated with antiIgM for 5 days scarcely divide beyond the first cell cycle (peak labeled A). In contrast, 31% of c-rel þ / þ ; bcl-x L Tg B cells entered the second cell cycle by day 3 (labeled B) and 12% entered the third cycle (labeled C). By day 5, over 55% of the cells had divided more than once compared with only 17% of c-rel
; bcl-x L Tg B cells. Simultaneous costaining of cells with CFSE and PI permits a more careful discernment of subpopulations undergoing arrest, growth, replication, and sequential divisions. Using this method, we determined whether viable cells progressed through each cell cycle successively or if they became blocked in a subsequent phase after completing the S phase. Apoptotic debris was first excluded based on forward scatter (FSC) and sidescatter (SSC) parameters, and cells in the viable gate (R1) used for staining analysis (Figure 1d , upper left panel). The bottom panels in Figure 1d show that greater than 96% of unstimulated B cells (0 h) are 
bcl-x L Tg B cells, at which time it is also observed that a substantial portion of crel þ / þ ; bcl-x L Tg B cells had divided at least once based on CFSE intensity. In comparison, virtually none of the c-rel
; bcl-x L Tg B cells have undergone cell division at 48 h. These results demonstrate that increased cell viability by Bcl-x L overexpression is not sufficient to restore cell cycle progression to c-rel
; bcl-x L Tg B cells beyond the first S phase in anti-IgM-treated cells. Together, these experiments suggest that c-Rel-dependent proliferative events are regulated independent of c-Rel-mediated survival via Bcl-x L , and indicate a unique role for c-Rel in controlling B-cell proliferation through modulation of the cell cycle. Our results also demonstrate that Bcl-x L activity alone is not sufficient to promote BCR-induced proliferation, and therefore cannot be the sole factor responsible for c-rel-associated lymphoid outgrowth.
Rb hyperphosphorylation and CDK activity are disrupted in c-rel
Rb proteins act as tumor suppressors by binding and blocking the transactivation domains of E2Fs in the nucleus, thereby repressing the transcription of several cell cycle genes, including various DNA replication factors such as dhfr, cdc6, and pol a (Fry et al., 1997; Dyson, 1998; Hateboer et al., 1998; Ohtani et al., 1998; Yan et al., 1998; Sherr and Roberts, 1999; Humbert et al., 2000; Wu et al., 2001; Weinmann et al., 2002) . To maintain cell cycle progression, CDK hyperphosphorylation of Rb on key serine and threonine residues is necessary for the inactivation of Rb and derepression of E2Fs during G 1 (Ezhevsky et al., 1997; Zarkowska and Mittnacht, 1997; Lundberg and Weinberg, 1998; Harbour et al., 1999; Ezhevsky et al., 2001) . In B cells, BCR ligation promotes the hyperphosphorylation of Rb by activated cyclin-CDK complexes. Our previous work indicates, however, that cell cycle activity may be affected in c-rel-deficient B cells .
To determine if cell cycle arrest in c-rel
; bcl-x L Tg B cells is a consequence of decreased CDK activity, we assayed the levels of phosphorylated Rb by immunoblotting. Hyperphosphorylated Rb can be separated from hypophosphorylated Rb by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and is easily detected as the upper band in anti-IgM-activated c-rel þ / þ ; bclx L Tg B-cell extracts at 36 h (Figure 2a, top panel) . We found that c-rel
; bcl-x L Tg B cells exhibit less hyperphosphorylated Rb compared to c-rel þ / þ ; bclx L Tg control cells with the ratio of upper to lower band intensity comparatively less in c-rel
; bcl-x L Tg extracts. We next determined whether the loss of Rb phosphorylation was specifically due to a lack of CDK4, CDK6, or CDK2 activity. Serine residues at positions 811 and 807 of Rb are reported to be CDK4 and CDK6 target sites, while a threonine residue at position 821 has been identified as a CDK2 target site (Knudsen and Wang, 1997; Zarkowska and Mittnacht, 1997) . As Figure 2a indicates, all three sites are unphosphorylated in unstimulated B cells, but undergo phosphorylation upon treatment with anti-IgM for 48 h. c-rel
; bclx L Tg B cells are less phosphorylated on Rb-S807/S811 and Rb-T821, however (Figure 2a) , indicating an overall loss of CDK4/6 and CDK2 activity. Radioactive kinase measurements also reveal an impairment of CDK2 activity in c-rel
; bcl-x L Tg B cells versus controls (Figure 2c ).
We next determined that loss of CDK2 kinase activity was not a consequence of elevated levels of p27 KIP1 , a CDK2 inhibitor, since normal downregulation of p27 KIP1 protein was observed in c-rel
; bcl-x L Tg B cells (Figure 2a) . The total expression of CDK2 protein was also unaffected (Figure 2a ), suggesting that c-Rel does not alter CDK expression levels. However, cyclin E expression was reduced in c-rel
; bcl-x L Tg B cells (Figure 2b ), indicating that loss of Rb phosphorylation and reduction of CDK activity could possibly result from insufficient cyclin E levels, since it is known that cyclin E is the major activator of CDK2 in late G 1 phase.
Another Rb-related protein, p107, functions similarly to Rb by forming a repressor complex with E2Fs and must be phosphorylated likewise for inactivation. It is induced during late G 1 and is thought to be required for progression into S phase by directing the timely expression of S phase genes (Moberg et al., 1996; Hurford et al., 1997; Smith et al., 1998) . As shown in Figure 2a , p107 expression is induced at 48 h in c-rel
bcl-x L Tg B cells. This persistent loss of p107 expression may reflect deficiencies in E2F activation since the p107 gene has been identified as an E2F transcriptional target (Lavia and Jansen-Durr, 1999) .
Together, our results suggest that the absence of c-rel in B cells has a negative impact on cell cycle progression by failing to induce proper CDK kinase activity, p107 expression, and Rb phosphorylation, which cannot be restored by simply increasing cell survival through bclx L overexpression.
E2F activity is impaired in c-rel
E2F activity is critical to G 1 progression and S phase entry (Weinberg, 1995; Dyson, 1998; Leone et al., 1998 Leone et al., , 1999 . Analysis of conditional E2F mutants, for instance, has shown that loss of E2F3 can severely impair the proliferative capacity of mouse embryonic fibroblasts, while combined loss of E2F1, E2F2, and E2F3 completely abolishes S phase entry (Humbert et al., 2000; Wu et al., 2001) . To determine if E2F activity and expression is dependent on the presence of c-rel, we analysed c-rel
; bcl-x L Tg B cells for E2F protein levels, DNA binding, and transcriptional activity. We found that BCR induction of E2F protein expression in c-rel
; bcl-x L Tg B cells is only slightly lower than that of control cells ( Figure 2a) ; however, submaximal E2F
bcl-x L Tg B cells by gelshift assay compared with control cells, correlating with increased levels of repressor-bound E2F complexes in 36 h samples (Figure 2d ). Supershift analysis using antibodies specific for p107, p130, and E2F4 confirmed the presence of p130/E2F in unstimulated lysates (0 h) and p107/E2F complexes in 36 h anti-IgM lysates (data not shown, see supplementary data I for Figure 5 ). In wild-type cells, p130/E2F complexes are typically found in unactivated G 0 cells, while Rb/E2F complexes are detected throughout the G 1 and S phases, and p107/E2F complexes are observed at the G 1 /S border (Moberg et al., 1996; Hurford et al., 1997; Smith et al., 1998; Furukawa et al., 1999) . (Complexes containing the Rb protein itself or other E2F family members could not be verified due to lack of available supershifting antibodies.) Both p130/E2F and p107/E2F complexes were consistently greater in anti-IgM-treated c-rel
; bclx L Tg B-cell extracts compared to controls (Figure 2d , compare lane 4 with lane 2), indicating that cell cycle progression might be restricted in the absence of c-Rel due to insufficient phosphorylation and inactivation of Rb family proteins as demonstrated in Figure 2a .
Correlating with these results, we found that several E2F transcriptional target genes were also reduced in both c-rel À/À and c-rel
; bcl-x L Tg B cells. Dihyrofolate reductase (DHFR) and CDC6 each play an important Immunoblots show the phosphorylation of Rb and related protein p107 using antibodies specific for mouse Rb (top panel), phosphoRb S807/S811 (second panel), phospho-Rb T281 (third panel), and p107 (fourth panel). Blots were stripped and reprobed with STAT6 to verify equal loading (fifth panel). Immunoblots showing comparable levels of E2F1, E2F3, E2F4 expression (seventh-ninth panels) and normal p27 KIP1 downregulation (sixth panel). Blots were stripped and reprobed with anti-CDK2 to show even loading (10th panel) (b) Splenic B cells were cultured with 10 mg/ml antiIgM for 48 h and assayed for endogenous cyclin E levels by immunoblotting using a mouse-specific cyclin E antibody. CH31 B cells were used as a positive control (CH31) and unstimulated bclx L Tg B cells were used as a negative control for cyclin E expression (c). The blot was stripped and reprobed with anti-CDK2 antibody to verify equal loading. (c) Splenic B cells were cultured in the presence or absence of 10 mg/ml anti-IgM for 48 h and immunoprecipitated CDK2 assayed for kinase activity by radioactive assay using histone H1 as a substrate. As a negative control, rabbit Ig sera (rIg) was used to immunoprecipitate 48 h anti-IgM-stimulated c-rel þ / þ ; bcl-x L Tg B-cell extracts. CH31 B-cell extract served as a positive control (c). (d) Whole-cell extracts from splenic B cells cultured with or without 10 mg/ml anti-IgM for 36 h were measured for DNA-binding activity by electrophoretic mobility shift assay using a radiolabeled E2F-specific probe. The indicated position of p130/E2F appears in 0 h unstimulated cells (lanes 1 and 3), whereas free E2F and p107/E2F complexes appear in 36 h anti-IgMstimulated cells (lanes 2 and 4), as determined by antibody supershift experiments (data not shown, see supplementary data I). (e) RT-PCR experiments were performed on anti-IgMstimulated B cells stimulated over a course of 48 h to measure the relative transcription levels of E2F target genes cdc6 and dhfr, and cyclin E1 using gene-specific primers. Gapdh serves as a control Cyclin E and bcl-x L restore cell cycle in c-rel À/À B cells S Cheng et al role in DNA replication and both genes are reported to be direct E2F transcriptional targets (Fry et al., 1997; Hateboer et al., 1998; Ohtani et al., 1998; Yan et al., 1998; Humbert et al., 2000; Wu et al., 2001) . Using the housekeeping gene gapdh as a normalization control, we found that both DHFR and CDC6 are induced in wildtype and c-rel þ / þ ; bcl-x L Tg B cells undergoing antiIgM-induced S phase between 24-48 h by RT-PCR, but are only poorly induced in c-rel À/À and c-rel
; bcl-x L Tg B cells (Figure 2e ). We also detected significant reductions in cyclin E RNA and protein levels in crel À/À and c-rel
; bcl-x L Tg B cells compared to controls (Figure 2e, b) . Since cyclin E is a well-described E2F target gene (Ohtani et al., 1995; Botz et al., 1996; Geng et al., 1996) , these findings are consistent with observed losses in E2F activity (Figure 2d ), and furthermore provide a possible explanation for the loss of CDK2 kinase activity in c-rel
; bcl-x L Tg B cells (Figure 2c ). Together with the gel-shift results, our data suggest that insufficient E2F activity, but not loss of E2F expression, is likely to play a role in the poor proliferation response of c-rel
; bcl-x L Tg B cells, and may be linked to deficient cyclin E induction during upstream signaling events. Our results also demonstrate that Bcl-x L activity alone cannot account for cell cycle defects of c-rel-deficient B cells.
Exogenous cyclin E and Bcl-x L cooperatively restore cell cycle progression
As the loss of CDK activity is presumed to be the primary cause of Rb hypophosphorylation and E2F repression in c-Rel-deficient B cells, we next attempted to restore kinase activity by supplementing excess exogenous cyclin E using a protein transduction method to reconstitute c-rel À/À ; bcl-x L Tg B cells. Cyclin E is reported to have essential functions in promoting S phase in both E2F-dependent and E2F-independent capacities, and contributes to G 1 progression by activating CDK2 (Duronio et al., 1996; Lukas et al., 1997; Leone et al., 1999; Sherr and Roberts, 1999; Beier et al., 2000) . Interestingly, reports have also shown that cyclin E can actually associate with NF-kB/Rel in the nucleus, suggesting that cyclin E and NF-kB/Rel may cooperate physically to induce proliferation (Chen and Li, 1998) . Since primary B cells are also notoriously resistant to DNA transfection or retroviral infection, however, we sought an alternative method to reconstitute c-rel-deficient B cells with missing cyclin E activity.
The TAT fusion protein transduction system utilizes a short peptide sequence derived from the HIV TAT protein to transport fusion proteins rapidly across cell membranes into cells and can also deliver proteins into nuclei (Nagahara et al., 1998; Schwarze et al., 1999; Ezhevsky et al., 2001) . Using this method, we have shown the rapid and efficient transduction of whole proteins into primary B lymphocytes previously . Our goal was to use TAT-cyclin E on c-rel
; bcl-x L Tg B cells to restore CDK2 activity and other cyclin E-dependent processes. We first determined whether TAT fusion proteins could be efficiently transduced into primary B cells by measuring the ability of splenic B cells to uptake TAT-cyclin E conjugated with a stable fluorescent dye, AF488. As demonstrated in Figure 3a , more than 495% of both c-rel þ / þ ; bcl-x L Tg and c-rel
; bcl-x L Tg B cells are transduced with TAT-cyclin E after 3 h, reaching 99% by 5 h. An autofluorescent TAT-green fluorescent protein (GFP) protein was also included in all subsequent experiments as a negative control. The relative purity of both TAT-GFP and TAT-cyclin E was verified by SDS-PAGE analysis, as shown in Figure 3b , demonstrating that each protein eluted as a pure fraction represented by a single band.
To further confirm that TAT proteins were capable of entering intracellular compartments, we used confocal microscopy to visualize the presence of each protein inside splenic B cells. As Figure 3c shows, TAT-cyclin E was detected in both the cytoplasm and nuclei of primary B cells within 3 h of incubation. Efficient subcellular localization was also detected for TAT-GFP, and could be observed in both c-rel þ / þ ; bcl-x L Tg and c-rel
; bcl-x L Tg B cells (Figure 3c ).
We next ascertained whether TAT-cyclin E retained the ability to bind and activate endogenous CDK2 in B cells. B cells from c-rel þ / þ ; bcl-x L Tg mice were cultured with TAT-cyclin E and control protein (TAT-GFP) in the presence of anti-IgM for 48 h. Nickel-agarose beads were then used to coprecipitate His-tagged TAT-cyclin E and TAT-GFP from cellular extracts, followed by SDS-PAGE separation and immunoblotting with anti-CDK2 antibody. Coprecipitated TAT-cyclin E and TAT-GFP controls were also evaluated for CDK2 kinase activity by radioactive assay using histone H1 as a substrate. As shown in Figure 3d , TAT-cyclin E was able to bind and activate endogenous CDK2 efficiently, demonstrating that the protein was stable for up to 48 h. Meanwhile, TAT-GFP had very little binding or kinase activity as anticipated. Based on these observations, we predicted that TAT-cyclin E would retain the functional properties of endogenous cyclin E and could potentially restore CDK2-mediated cell cycle progression to c-rel
; bcl-x L Tg B cells. Our next experiment was to determine whether TATcyclin E could reestablish cell cycle progression in c-rel
; bcl-x L Tg B cells. Proliferation assays by thymidine incorporation showed that TAT-cyclin E, but not TAT-GFP, could almost completely restore DNA synthesis in c-rel
; bcl-x L Tg B cells in a dosedependent manner (Figure 4a ). Addition of TAT-cyclin E also enhanced DNA synthesis in c-rel (Figure 4a ). However, TAT-cyclin E was not able to fully restore cell cycle activity in the absence of Bcl-x L , suggesting that cyclin E and Bcl-x L act cooperatively to induce robust B-cell proliferation responses in response to c-Rel signaling. Furthermore, transduction of B cells with TAT-CDK2DN (a dominant-negative CDK2 mutant) can efficiently block antiIgM-induced proliferation of wild-type B cells (see supplementary data III), thus demonstrating that cyclin
E is a rate-limiting factor for S phase entry in BCRinduced proliferation.
Cells were then costained with CFSE-PI to evaluate the cell cycle distribution and cellular division of reconstituted cells by flow cytometry. As shown in Figure 4b , TAT-cyclin E could dramatically enhance the ability of primary c-rel
; bcl-x L Tg B cells to overcome the G 1 arrest imposed by c-Rel deficiency in anti-IgMcultivated cells. The percentage of TAT-cyclin E-treated c-rel
; bcl-x L Tg B cells entering S-G 2 /M phases (35%) was increased by ninefold over TAT-GFP controls (4%) in the presence of anti-IgM. Meanwhile, c-rel þ / þ ; bclx L Tg B cells were also efficiently driven into cycle by TAT-cyclin E (64% in S-G 2 /M), which was nearly a twofold improvement over anti-IgM alone (36% in S-G 2 /M). Thus TAT-cyclin E, but not TAT-GFP, is able to increase the entry of B cells into S phase for both c-rel þ / þ ; bcl-x L Tg and c-rel
; bcl-x L Tg mice. Interestingly, TAT-cyclin E-treated c-rel
; bcl-x L Tg B cells could not actually be detected in the second round of cell cycle by CFSE-PI staining, as compared to c-rel þ / þ ; bcl-x L Tg control cells (Figure 4b) . Thus, additional cRel-dependent cell cycle activities are missing in TATcyclin E-treated c-rel
; bcl-x L Tg B cells, despite enhanced S phase entry (see below). Nevertheless, our Figure 1a supplemented with 100 nm TAT-cyclin E, 300 nm TAT-cyclin E, 300 nm TAT-GFP, or control media. At t ¼ 42 h, cells were pulsed with 0.5 mCi [ 3 H]thymidine for an additional 6 h, and harvested for scintillation counting. (b) CFSE-labeled c-rel þ / þ ; bcl-x L Tg and c-rel À/À ; bclx L Tg B cells were cultured with 300 nm TAT-cyclin E and 300 nm TAT-GFP control protein in the presence or absence of anti-IgM. At t ¼ 0 and 48 h, cells were stained with PI and analysed by flow cytometry. Percentages of cellular subsets were calculated as described in Figure 1d Cyclin
results support the notion that c-Rel regulates at least one component of the cell cycle by eliciting necessary functions of cyclin E-CDK2 activity to drive cells through G 1 and S phases.
CDK2 and Rb-E2F activity are restored to c-rel
bcl-x L Tg B cells by cyclin E To further confirm that TAT-cyclin E promotes G 1 and S phase progression by enhancing CDK2 activity, we evaluated downstream cell cycle events in the cyclin CDK and Rb-E2F pathways. TAT-cyclin E, but not TAT-GFP, was able to increase the phosphorylation of Rb dramatically in both c-rel þ / þ ; bcl-x L Tg and c-rel
; bcl-x L Tg B cells treated with anti-IgM (Figure 5a ). This boost in activity correlated with decreased amounts of p130/E2F and p107/E2F repressor complexes as determined by gel-shift assay (Figure 5b and see supplementary data I), and also elevated levels of CDC6 and DHFR transcripts by RT-PCR (Figure 5c ). Thus with the cooperation of Bcl-x L -mediated survival, TATcyclin E transduction is able to over-ride the cell cycle block in arrested c-rel À/À B cells and promotes CDK2-dependent phosphorylation of Rb as well as E2F derepression.
Cyclin E does not restore G 2 /M phase progression in c-rel
Although TAT-cyclin E can promote c-rel
; bcl-x L Tg B cells to undergo G 1 progression and S phase replication, the cells appear to be blocked in the G 2 /M phase with very few cells reappearing in the second round of cycling (see Figure 4b ). To determine if this phenomenon resulted from insufficient cyclin A and cyclin B levels, we assayed the levels of these two proteins in TATcyclin E-treated B cells by Western blot. Cyclin A partners with CDK2 during S phase while cyclin B partners with CDK1 during G 2 /M phase. As Figure 5d indicates, both cyclin A and cyclin B protein levels are deficient in the absence of c-rel. However, cyclin A levels are restored upon treatment of cells with TAT-cyclin E, consistent with the observed progression of cells through S phase (Figure 5d ). Cyclin B, on the other hand, appears only to be partially rescued, and could thus Figure 5 TAT-cyclin E enhances CDK2 kinase activity, pRb phosphorylation, and E2F activity. (a) Resting splenic B cells were cultured in the presence or absence of 10 mg/ml anti-IgM, 300 nm TAT-cyclin E, 300 nm TAT-GFP, or control media. At 48 h, cells were harvested, lysed, and samples were immunoblotted with phosphospecific anti-Rb T821. Blots were stripped and reprobed with STAT6 to verify equal loading. (b) Cells were cultured and lysed as described in (a) and DNA-binding activity was assayed using a radiolabeled E2F-specific probe. Antibody supershift experiments (data not shown, see supplementary data I) indicate that p130/E2F complexes are found in the upper band of unstimulated cells (lanes 2 and 5), while p107/E2F complexes appear in 36 h anti-IgM-stimulated cells (lanes 3, 6, and 7). Free E2F complexes are elevated in both TAT-cyclin E-transduced B cultures (lanes 4 and 7). The continuously dividing B cell line CH31 was included as a control (C) and consists primarily of free E2F (lane 1). (c) Cells were prepared as described in (a) and harvested at 24 h for RT-PCR experiments using primers specific for cdc6, dhfr, and gapdh. (d) Resting splenic B cells were cultured in the presence or absence of 10 mg/ml anti-IgM, 300 nm TAT-cyclin E, 300 nm TAT-GFP, or control media. At 48 h, cells were harvested, lysed, and samples assayed for the expression of cyclin A and cyclin B by Western blot. NS indicates nonspecific bands used to visualize equal loading. A indicates the inducible cyclin A band, and B indicates the inducible cyclin B band. (e) Resting splenic B cells were cultured for 48 h in the presence of 10 mg/ml anti-IgM and assayed by RT-PCR using primers specific for cdc25a and cak explain the inability of the cells to progress beyond G 2 and M phases.
In addition to these results, we found that the expression of two genes that modulate CDK activity in the G 2 /M phase, cdc25a phosphatase and cdkactivating kinase (cak) were either insufficiently induced or delayed in anti-IgM-treated c-rel À/À and c-rel
; bclx L Tg B cells compared to controls (Figure 5e ). CDC25A removes inhibitory phosphate groups on CDK1, while CAK activates CDK1 by phosphorylation. Both must be turned on in G 2 /M phase to activate cyclin B-CDK1 complexes for cell cycle progression through G 2 and M phases; however, in the absence of c-Rel, neither gene is sufficiently induced. Combined with the loss of cyclin B expression in c-Rel-deficient cells, these results suggest that multiple downstream events are impaired in the absence of c-Rel that contribute to the inability of c-rel
bcl-x L Tg B cells to undergo G 2 /M phase, regardless of whether TAT-cyclin E is present to drive them through G 1 and S phases.
c-Rel controls E2F3a expression in B cells
As the link between c-Rel and cyclin E expression was still unknown, we next attempted to test putative kB binding sites in the cyclin E promoter for NF-kB/Relbinding activity. Three potential binding sites were identified at positions À3255, À1277, and À1138 bp upstream of the ATG translational start site, and each one was evaluated for NF-kB/Rel DNA-binding activity by gel-shift assay. The results suggested that none of the sites were bound by NF-kB/Rel in B cells (data not shown). As cyclin E is an established E2F3 target gene (Humbert et al., 2000) , and c-Rel-deficient B cells exhibit reduction in E2F activity (see Figure 2d , e), we then sought to determine whether e2f3 might be a c-Rel target gene.
A second isoform of E2F3 was recently discovered, caused by the transcription of an alternative exon, leading to two distinct gene products, E2F3a and E2F3b, whose difference lies only in the first exon. E2F3a is induced by mitogenic stimuli and is involved in cellular growth and proliferation responses similar to E2F1 and E2F2, while E2F3b is constitutively expressed and can be detected in E2F3b-Rb-repressor complexes of quiescent cells much like E2F4 and E2F5 Adams et al., 2000; Leone et al., 2000; Wu et al., 2001) . Hence, we examined whether e2f3a might be a c-Rel target gene responsible for cell cycle induction in B cells. Interestingly, the E2F3 Western blot results we obtained in Figure 2a indicate that E2F3 expression is not markedly reduced in c-rel
; bcl-x L Tg B cells. However, the antibody used in these experiments was not able to discriminate between the E2F3a and E2F3b isoforms, and since an E2F3a-specific antibody is not currently available, we used RT-PCR to measure the induction of E2F3a. We found that c-rel
; bcl-x L Tg B cells are in fact deficient for the expression of E2F3a (Figure 6a ). These results suggested that the observed loss of E2F activity in c-rel
; bcl-x L Tg B cells might be related to defects in e2f3a gene expression. Site I corresponds to À864 bp upstream of the ATG translational start site ( þ 1) and site II is located À214 bp upstream. (c) Cells were cultured as described in (b) and assayed for NF-kB/Rel-binding activity by gel-shift assay using a radiolabeled probe containing the À864 kB site and antibodies specific for p50, p65, and c-Rel to supershift complexes. The inducible complex (labeled A) is supershifted by p50, c-Rel, and p65 antibodies in wild-type B cells stimulated with 10 mg/ml anti-IgM, but a mutated site (À864 kBMUT) prevents the binding of these complexes. (Supershifted complexes do not visibly migrate, but appear lighter than nonshifted control bands instead.) An additional site (À214 kB) does not appear to bind any NF-kB/ Rel complexes either. Complex B represents nonspecific binding activity that serves to show equal loading of lanes. (d) CH31 B cells stimulated with 10 mg/ml anti-CD40 also exhibit c-Rel and p50 binding activity (labeled A) at the À864 kB site of the e2f3a promoter but a mutant À864 kB site and the À214 kB site do not bind. (e) WEHI 231 B cells stimulated with 10 mg/ml anti-CD40 show NF-kB/Rel binding activity (labeled A) while the mutant À864 kB site and À214 kB site do not exhibit any NF-kB/Relbinding activity. (f) A total of 1 Â 10 5 NIH 3T3 cells were transfected with 0.5 mg of firefly luciferase constructs containing a 2 kb e2f3a promoter (E2F3a-luc), a mutant 2 kb promoter (MUTluc) bearing a mutation at the À864 kB site, or a positive control Igk chain promoter (Igk-luc), and cotransfected with either 0.5 mg of p50, c-Rel, or empty expression vector (pcDNA3). Cells were also cotransfected with a Renilla luciferase internal control plasmid containing a thymidine kinase promoter (tk-pRL) to drive constitutive Renilla luciferase activity for normalization of data. At 48 h, cells were harvested and assayed for firefly and Renilla luciferase activity. All experiments were carried out in triplicate and repeated in three separate experiments. A representative set of data is shown Cyclin E and bcl-x L restore cell cycle in c-rel
We next sought to determine whether the e2f3a gene might be a direct target for NF-kB/Rel. As shown in Figure 6b , the e2f3a promoter contains two consensus kB-binding sites at positions À864 bp (site I) and À214 bp (site II) upstream of the ATG start site. Electromobility shift assays show that only site I is bound by c-Rel dimers from wild-type primary B cells, while site II is not bound by c-Rel (Figure 6c ). Mutation of site I (À864 kB MUT) completely abolished binding by c-Rel. Complexes containing p50 and p65 also bound to site I in extracts from wild-type B cells (Figure 6c ). In addition to these results, two B-cell lines (CH31 and WEHI 231 B lymphoma cells) were tested for NF-kB/ Rel-binding activity to sites I and II, with both exhibiting significant c-Rel binding at site I, while the mutated site at position À864 bp, and the second kB site at position À214 bp (site II), did not bind any of the three NF-kB/Rel proteins (Figure 6d, e) . To demonstrate that the cell extracts actually contained inducible NF-kB-Rel complexes and that the supershifting antibodies were indeed functional, we used a radiolabeled probe derived from the immunoglobulin kappa light chain promoter (Igk) as a positive control to perform gel-shift assays on the same extracts. As shown in Figure 6d , NF-kB/Rel complexes could be readily detected in B-cell lysates and were inducible by mitogenic signaling.
Consistent with these results, transcriptional activation of the e2f3a promoter by c-Rel was observed in NIH 3T3 cells transfected with a luciferase reporter vector, whereas an empty control vector induced only minimal luciferase activity. Activation of the e2f3a promoter was increased more than fourfold by the expression of c-Rel in these cells, and was noticeably decreased when the À864 kb-binding site was mutated (Figure 6f ). Activation of a positive control promoter derived from the immunoglobulin kappa light chain gene (Igk-luc) indicated that c-Rel-mediated induction of E2F3a was significant, and furthermore exhibited comparable induction of the Igk-luc-positive control reporter. Interestingly, although p50 DNA-binding activity was identified in the gel-shift assays, the expression of p50 did not upregulate luciferase activity. Since p50 lacks a transactivation domain, these results could indicate that p50 binds the e2f3a promoter as a repressor rather than a transcriptional activator. Taken together, the data from these experiments indicate that e2f3a is in fact a bona fide target gene of c-Rel, and may possibly function as the missing link between c-Rel and control of the cell cycle.
Discussion
Clonal expansion of antigen-specific lymphocytes is a critical feature of the adaptive immune system. The importance of c-rel in controlling this response is clear; however, the exact mechanism by which c-rel promotes cell cycle progression in lymphocytes has only recently begun to unravel. Given its essential function in promoting the proliferation and survival of B cells, it is not surprising that overexpression and amplification Cyclin E and bcl-x L restore cell cycle in c-rel À/À B cells S Cheng et al of c-Rel activity is associated with various lymphoid malignancies. The effort to understand this response is therefore paramount to establishing efficient therapies for the treatment of various c-rel-associated lymphoproliferative disorders, including several leukemias and lymphomas.
As mature c-rel À/À B cells lack inducible bcl-x L expression, they are hypersensitive to BCR-induced growth arrest and apoptosis. Our present study shows that overexpression of Bcl-x L alone can restore survival to c-rel
; bcl-x L Tg B cells, but does not increase proliferation and cell cycle progression through G 1 and S phases. However, the fact that Bcl-x L expression does not completely rescue BCR-induced apoptosis, may reflect the importance of other survival factors such as Bfl-1 and Mcl-1 that are also induced in anti-IgMstimulated B cells (Grumont et al., 1999; Zong et al., 1999; Chen et al., 2000; Grossmann et al., 2000; Bernal et al., 2001; Hinz et al., 2001; Owyang et al., 2001; Tumang et al., 2002; Edelstein et al., 2003) . In addition, deficiencies in cyclin E expression, CDK2 kinase activity, Rb phosphorylation, and E2F activity are persistent in c-rel
; bcl-x L Tg B cells despite enhanced viability. These results imply that c-Rel controls lymphocyte survival and proliferation through distinct mechanisms, and suggests that key cell cycle regulators are downstream targets of c-Rel. These results also suggest that loss of cell cycle progression in c-rel À/À B cells is not a consequence of increased cell death, since restoration of cell survival by the bcl-x L transgene cannot compensate for defects in proliferation. We show here that coexpression of cyclin E with Bcl-x L can restore c-Rel-mediated proliferation and survival by reversing the cell cycle arrest and apoptosis of BCRactivated c-rel À/À B lymphocytes. Our work therefore illustrates a possible mechanism by which lymphocytes might break tolerance to induce autoimmunity or perhaps acquire the capacity for uncontrolled cell growth.
The idea that c-Rel may activate CDK kinase activity via the direct transcription of cyclins has been an attractive notion, as others have reported that NF-kB (p50/p65 heterodimers) can bind and activate transcription of the mouse cyclin D1 promoter (Guttridge et al., 1999; Hinz et al., 1999) . However, while aberrant activity of cyclin D1 is associated with numerous cancers (Sherr and McCormick, 2002) , cyclin D1 protein has not been detected in normal BCR-activated B lymphocytes, indicating that cyclin D1 activity is not relevant to mature B-cell proliferation. This does not necessarily exclude the possibility that cyclin D1 is involved in the oncogenesis of B-cell-specific lymphomas, but rather suggests that cyclin D1 misexpression in transformed B cells may in fact result from an independent transformation event that consequently contributes to dysregulated cell cycle control and tumorigenesis. It is interesting to note that although p50/p65 heterodimers can activate cyclin D1 expression in fibroblasts, p50 gene deletion in pre-B cells actually reduces transformation events elicited by the v-abl oncogene and correlates with decreased cyclin D1 expression (Nakamura et al., -mediated CDK2 inhibition (Bash et al., 1997) . These conflicting results underscore the differential properties of NF-kB/Rel proteins in cell types where they may not normally be expressed (i.e. transformed cell lines and fibroblasts), and emphasize that regulation of the cell cycle by NF-kB/Rel proteins is far more complex than currently understood.
Regulation of other cyclins by NF-kB/Rel proteins have not been reported, but direct activation of the cyclin E promoter by E2F has been clearly demonstrated (Botz et al., 1996; Ohtani et al., 1995) , and could potentially serve as a mechanistic link between c-Rel and cyclin E. Our current studies show that e2f3a gene expression and function is impaired in c-rel deleted B cells, correlating with impaired proliferative responses. We further show that e2f3a is a direct target of c-Relmediated gene transcription, whose expression coincides with the induction of c-Rel activity. c-Rel DNA-binding activity is sustainable for up to 36 h in BCR-stimulated B cells (supplementary data II), paralleling the induction of E2F3a expression and activity (see Figures 2d and  6a ). In contrast, we find that cyclin E is not a direct transcriptional target of c-Rel, despite the presence of three putative NF-kB/Rel-binding sites in the cyclin E promoter at positions À3255, À1277, and À1158 bp upstream of the ATG start site. Gel-shift assays reveal that none of these sites are bound by c-Rel in wild-type B-cell extracts (data not shown), suggesting that c-Reldependent intermediate factors such as E2F3a must mediate the expression of cyclin E during anti-IgMactivated B-cell proliferation rather than c-Rel directly activating the transcription of cyclin E.
Other modifiers of CDK activity include inhibition by CDK inhibitors (i.e. INK4 or p27 KIP1 families); however, we can exclude p27 KIP1 -mediated inhibition as a possible cause of G 1 arrest in c-rel À/À B cells because normal downregulation of p27 KIP1 protein is observed. We also find that CDK expression itself is unaffected by deletion of c-rel since both wild-type and c-rel À/À B cells exhibit equivalent amounts of CDK proteins throughout the cell cycle . Loss of G 1 CDK activity is therefore attributable to poor cyclin E induction. Since cyclin E associates stoichiometrically with CDK2 and p27 KIP1 /p21 CIP1 (Sherr and Roberts, 1999) , partial or subthreshold amounts of cyclin E in c-rel À/À ; bcl-x L Tg B cells would in theory be insufficient to titrate enough CDK2 away from p27 KIP1 /p21 CIP1 complexes necessary for the induction of adequate kinase activity during G 1 progression. Moreover, TAT-cyclin E transduction into B cells demonstrates that these signaling defects can be bypassed to drive cells into S phase.
Our findings therefore place c-rel in a critical position atop two signaling pathways, whereby BCRactivated c-Rel simultaneously induces Bcl-x L expression to promote cellular survival, and also promotes cyclin E-CDK2 and Rb-E2F activity via E2F3a induction to drive cells into cycle (Figure 7 ). This latter arm is further amplified by an autoregulatory loop in which cyclin E-CDK2 derepresses E2F, and free E2F in turn activates the transcription of cyclin E. Since E2F and Rb are implicated in numerous tumorigenic models, it is fathomable that c-Rel may trigger oncogenic mechanisms via activation of the Rb-E2F pathway, particularly given c-Rel's ability to concurrently induce cell survival mechanisms via bfl-1 and bclx L expression and cell cycle progression via cyclin-CDK activation.
The finding that TAT-cyclin E promotes S phase entry without increasing mitotic division in c-rel
; bcl-x L Tg B cells suggests that other factors important to G 2 and M phase progressions are under the control of c-Rel as well. This notion is corroborated by an observed persistence of c-Rel activity in normal anti-IgMactivated B cells over a period of 36 h (see supplementary data II) during which time several cells have already entered G 2 and M phases. Concomitantly, we find that cyclin B, CDC25A, and CAK expression are impaired in the absence of c-rel, all factors that would contribute to G 2 /M arrest. Alternatively, overexpressed TAT-cyclin E may be degraded after progression through the S phase due to natural turnover mechanisms activated in the G 2 or M phase, thus preventing a second round of cell cycle from ensuing. A third possibility is that c-rel
; bclx L Tg B cells are merely delayed for G 2 and M phase progression.
Collectively, our findings maintain that c-rel is not only a critical regulator of lymphocyte proliferation and survival but also suggest that NF-kB/Rel proteins play an important role in controlling lymphocyte homeostasis, tolerance, and activation. We conclude that inhibition of c-Rel or its downstream survival and cell cycle signaling pathways may be an effective means to block multiple disorders including graft rejection, allergy/inflammation, autoimmunity, and leukemia/ lymphoma. Indeed several new studies entertain this theory, many with very promising results (Aronica et al., 1999; Donovan et al., 1999; Davis et al., 2001; Finn et al., 2001; Hinz et al., 2001; Hilliard et al., 2002; Joos et al., 2002; Liu and Beller, 2002; Mason et al., 2002; Yang et al., 2002) .
Materials and methods
Mice, purification of murine splenic B cells, and cell culture
bcl-x L Tg, and c-rel
; bcl-x L Tg mice (all on a C57BL/6 background) were generated as described previously (Owyang et al., 2001) . Mice 8-12 weeks old were used in all experiments. Purified B cells (>95% B220 þ ) were enriched by complement-mediated lysis as described previously , and cultured in RPMI 1640 media containing 10% fetal calf serum (FCS) (Cellgro), 1% penicillin, 1% streptomycin (both Life Sciences BRL), and 50 mm b-mercaptoethanol (Sigma). ] by scintillation counter as described previously .
Cell cycle analysis by PI, CFSE staining, and flow cytometry A total of 2 Â 10 6 purified splenic B cells were cultured in 1 ml complete media mixed with 1 ml of 5 mm CFSE (Molecular Probes) dissolved in DMSO, and incubated for 10 min at 371C. After washing twice with complete media, 2 Â 10 5 B cells were cultured per well in 96-well plates and stimulated with 10 mg/ml anti-IgM in the presence or absence of various TAT fusion proteins (100-300 nm). At the indicated time points, cells were collected and stained with a solution containing 50 mg/ml PI, 20 mg/ml RNase A, 0.1% Triton X-100, and 0.1% sodium citrate, for 30 min at 41C. DNA content and cell cycle analysis were performed on a FACScalibur machine using CellQuest software (Becton Dickinson) as previously described (Andjelic et al., 2000) .
Immunoblotting
Cells were lysed in 50 mm HEPES (pH 7.5), 150 mm NaCl, 1 mm EDTA, 2.5 mm EGTA, 1 mm dithiothreitol, 0.1% Tween-20, 10% glycerol, 10 mm b-glycerophosphate, 1 mm sodium fluoride, 0.1 mm Na 3 VO 4 , 0.2 mm PMSF, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 2.5 mm sodium pyrophosphate, and protein concentrations determined by Bradford assay (Bio-Rad). In all, 30-40 mg of whole-cell lysate were loaded onto SDS-PAGE and transferred onto the PVDF membrane (Millipore). Blots were probed with the following antibodies diluted into 1% nonfat milk in tris-buffered saline solution containing 0. Cyclin E and bcl-x L restore cell cycle in c-rel À/À B cells S Cheng et al T821 (44-582) from Biosource; Rb S807/S811 (9308S) from Cell Signaling; antihemaaglutinin (HA) (12CA5) a gift from Dr Martin Scott. Horseradish peroxidase-conjugated antirabbit secondary antibody (NA934) and anti-mouse secondary antibody (NA931) were purchased from Amersham. ECL plus chemiluminescence detection system was used to visualize Western blots (RPN 2132) from Amersham. In all experiments, equal protein loading was controlled for by either stripping blots as previously described , and reprobing blots with anti-CDK2 or anti-STAT6, or in some cases verified by using nonspecific bands for comparison. All Western blot experiments have been confirmed in multiple experiments using separate sets of cell lysates. The data presented in the figure are representative of several independent experiments with similar results.
DNA-binding activity and electromobility shift assay. Splenic B cells were cultured in the presence or absence of 10 mg/ml anti-IgM with either 300 nm TAT-GFP, TAT-cyclin E, or control media. At the indicated time points, cells were harvested and lysed in buffer C (20 mm HEPES pH 7.6, 1.5 mm MgCl 2 , 0.42 m KCl, 25% glycerol, 0.1% NP-40, 0.2 mm EDTA, 1 mm PMSF, 1 mm DTT, 5 mg/ml pepstatin, 5 mg/ml leupeptin, 5 mg/ml aprotinin, 4 mm NaF, 4 mm sodium vanadate), and sonicated with 20 pulses at 41C. Samples were then centrifuged at 13 000 g for 10 min and pelleted debris were discarded. Radiolabeled probes were generated by annealing 200 ng of the following double-stranded sequences (only sense strands listed here): adenoviral E2F 5
0 , and single-stranded loop for IgkB5 0 -GAGAGGGGACTTTCCGATTAGCTTTCGG AA AGTCCCCTC-3 0 . Probes were end labeled with 5 mCi [ 32 P]gATP. For the binding reaction, 30-40 mg of each supernatant sample was incubated for 20 min on ice with the following: 40 000 c.p.m. radiolabeled probe in 10 mm Tris-HCl, pH 7.5, 1 mm DTT, 1 mm EDTA, pH 7.5, 5% glycerol, 0.1 mg/ml polydIdC (Boehringer Mannheim), and 0.5% NP-40. Buffer C was used to balance the reaction to a final concentration of 200 mm KCl in a total volume of 20 ml. Reaction samples were then resolved on a 6% PAGE in 0.25 Â tris-borate-EDTA buffer for 3 h at 160 V, dried onto filter paper (Whatman), and exposed overnight on film. Supershift analysis was performed using 5-7 mg anti-p130 (sc-317 Â ), anti-p107 (sc-317 Â ), anti-cRel (sc-071) Santa Cruz Biotechnology, anti-p50 from previous studies (Liou et al., 1994) , and anti-p65 (RelA; 100-4165) from Rockland.
RT-PCR
Splenic B cells were cultured in 10 mg/ml anti-IgM for a duration of 48 h. Total RNA preparation and reverse transcription were carried out as described in Hsia et al. (2002) . Genes were amplified by PCR using mouse-specific primers: cyclin E1 ( 0 (À). PCR products were separated on 2% agarose containing ethidium bromide in tris-acetate-EDTA buffer.
Generation of TAT fusion proteins and conjugation with a fluorescent AF488 label Purified TAT fusion proteins, containing eGFP (TAT-GFP) and cyclin E (TAT-cyclin E), were generated as previously described . TAT cloning vectors contain a histidine (His) tag for nickel column purification and an HA tag for rapid immunodetection (Nagahara et al., 1998) . To observe the efficiency of TAT fusion protein transduction into primary B cells directly, cells were cultured with either purified TAT-GFP and measured directly for GFP fluorescence by flow cytometry or purified TAT-cyclin E conjugated with a fluorescent chemical Alexa Fluor 488 (AF488) (Molecular Probes). Briefly, 1 mg of TAT-cyclin E protein was placed into a 0.3 ml reaction volume for 2 h according to the manufacturers' protocol. Excess unconjugated AF488 was then removed by gel filtration (column provided by the manufacturer). The efficiency of AF488 crosslinking was determined by spectrophotometry at 494 nm OD using a molar extinction coefficient of A 494 ¼ 71 000/cm/m. Roughly, two to four molecules of AF488 were conjugated per molecule of TAT fusion protein on average. TAT-CDK2 and TAT-CDK2DN containing a point mutation in the kinase domain were a gift from Dr Steven Dowdy.
Confocal microscopy
To visualize the subcellular localization of transduced TATfusion proteins, primary B cells were cultured with 50 nm TAT-GFP or 50 nm AF488-labeled TAT-cyclin E for 3 h, and then washed and fixed for 15 min in 0.5% paraformaldehyde before mounting on 35 mm Petri dishes containing 14 mm microwells with coverslips (Mat Tek). Samples were then analysed by confocal microscopy.
His-tagged TAT-fusion protein pull-down assays
A total of 2 Â 10 7 B cells were incubated with TAT fusion proteins in the presence of 10 mg/ml anti-IgM for 48 h. Cells were then collected at the indicated times, washed once in phosphate-buffered saline (PBS), and lysed in 1 Â PBS, 20 mm imidazole, 1 mm PMSF, and 0.05% Tween-20 (lysis buffer P). His-tagged TAT fusion proteins were then pulled down by adding 50 ml of Ni-NTA resin (Qiagen) pre-equilibrated in lysis buffer P to 500 mg of cell lysate and incubated for 1 h at 41C while rotating. Samples were then centrifuged at 2000 g for 1 min, washed three times with buffer P, and analysed by immunoblotting with the appropriate antibody or by kinase assay as described below.
Immunoprecipitation and kinase assays
A total of 100-200 Â 10 6 primary splenic B cells were cultured in 10 mg/ml anti-IgM either alone or with 300 nm TAT-GFP or 300 nm TAT-cyclin E. Cells were then washed once in PBS, lysed in Rb lysis buffer, centrifuged at 13 000 g, and supernatants were quantitated by Bradford assay (Bio-Rad). Immunoprecipitation with anti-CDK2 antibody (sc-163, Santa Cruz) and kinase assays were performed as described previously using 250-400 mg of whole-cell extract and histone H1 (Boehringer Mannheim) as a substrate.
Transfection and luciferase assays
E2F3a-luc (pGL2-E2F3ap) was a gift from Dr Gustavo Leone Leone et al., 2000) , Igk-luc (pBII-luc) and CDM8-p50 expression vector (p50) from previous studies (Liou et al., 1994) , MIGR1-GFP from (Pui et al., 1999) , and tk-pRL obtained from Dr Paolo Casali's lab. À864 kBMUTluc was constructed by inserting a BclI restriction site into the NF-kB/Rel-binding site of the mE2F3a promoter at À864 bp upstream of the ATG translational start site. c-Rel was constructed by amplifying a 30 amino-acid C-terminal truncation mutant of c-Rel using 5 0 -TGAATTCATGGCCTC-GAGTGGATATA AT-3 0 forward PCR primer and 5 0 -ATTCTAGATTAATTATTTGCGTCATCTGATAGTCC-3 0 reverse primer, and subcloning the fragment into EcoRI and XbaI sites of pcDNA3-HA. A total of 0.5 Â 10 5 NIH 3T3 cells were plated per well in 24-well plates and transfected with 2 ml lipofectamine 2000 (Invitrogen), then cultured in 0.5 ml media containing 1% FCS and 0.5 mg of the following reporter vectors: E2F3a-luc, Igk-luc, or À864 kBMUT-luc in the presence or absence of 0.5 mg of the following expression vectors: c-Rel, CDM8-p50, or empty vector control (pcDNA3-HA). At 48 h, cells were washed once in PBS, lysed in passive lysis buffer, centrifuged at 13 000 g, and supernatants were assayed for luciferase activity using a commercial kit (Promega). Transfection efficiency was determined by GFP analysis using flow cytometry to measure MIGR1-GFPtransfected cells.
Abbreviations CDK, cyclin-dependent kinase; IL-2, interleukin-2; IL-4, interleukin-4; IL-12, interleukin-12; PI, propidium iodide; GFP, green fluorescent protein; CFSE, 5-(and-6)-carboxyfluoresceindiacetate succinimidyl ester; DHFR, dihyrofolate reductase.
